Please login to the form below

Not currently logged in
Email:
Password:

Former Pfizer VP James Taylor joins INC Research

He was previously VP global clinical trial management at the US pharma firm

INC Research, James TaylorINC Research has appointed Pfizer's former head of clinical trials James Taylor as its new VP, clinical development.

Taylor, who was VP, global clinical trial management at Pfizer, joins the clinical research organisation (CRO) immediately, and will act as the primary liaison between INC Research and its biopharma customers.

It is the second major personnel change during 2013 for INC Research following the appointment of former chief operating officer Jamie Macdonald to CEO in January.

Macdonald commented on the decision to hire Taylor: "Jim is an accomplished leader with global experience across all phases of complex enterprise operations involving the execution of clinical trials."

He added: "Having worked in large pharma for many years, he brings a strong customer perspective, which allows him to anticipate our customers' needs and communicate their requirements more effectively.”

Taylor spent almost a decade at Pfizer, initially serving as VP, worldwide head contracts and outsourcing before assuming his role in clinical trial management.

Prior to joining Pfizer, Taylor served at Sanofi as senior director outsourcing management and he has also held positions at Baxter Healthcare and Omnicare Clincial Research.

12th March 2013

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics